Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005642 · ClinicalTrials.gov registry record · Phase 1
SU5416 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00005642 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 19 participants.
The verdict
NCT00005642, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have advanced solid tumors.
Interventions
- DRUG semaxanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2000-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005642
The ClinicalTrials.gov registry entry for NCT00005642 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which semaxanib is the first listed.
NCT00005642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005642 about?
NCT00005642 is a clinical study titled "SU5416 in Treating Patients With Advanced Solid Tumors". RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have advanced solid tumors.
What is the current status of trial NCT00005642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2000-05. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00005642?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00005642?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.